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Abstract
Background and Objectives Uncertainty exists regarding the optimal dosing regimen for vancomycin in different patient 
populations, leading to a plethora of subgroup-specific pharmacokinetic models and derived dosing regimens. We aimed to 
investigate whether a single model for vancomycin could be developed based on a broad dataset covering the extremes of 
patient characteristics. Furthermore, as a benchmark for current dosing recommendations, we evaluated and optimised the 
expected vancomycin exposure throughout life and for specific patient subgroups.
Methods A pooled population-pharmacokinetic model was built in NONMEM based on data from 14 different studies in 
different patient populations. Steady-state exposure was simulated and compared across patient subgroups for two US Food 
and Drug Administration/European Medicines Agency-approved drug labels and optimised doses were derived.
Results The final model uses postmenstrual age, weight and serum creatinine as covariates. A 35-year-old, 70-kg patient 
with a serum creatinine level of 0.83 mg dL−1 (73.4 µmol L−1) has a V1, V2, CL and Q2 of 42.9 L, 41.7 L, 4.10 L h−1 and 
3.22 L h−1. Clearance matures with age, reaching 50% of the maximal value (5.31 L h−1 70 kg−1) at 46.4 weeks postmen-
strual age then declines with age to 50% at 61.6 years. Current dosing guidelines failed to achieve satisfactory steady-state 
exposure across patient subgroups. After optimisation, increased doses for the Food and Drug Administration label achieve 
consistent target attainment with minimal (± 20%) risk of under- and over-dosing across patient subgroups.
Conclusions A population model was developed that is useful for further development of age and kidney function-stratified 
dosing regimens of vancomycin and for individualisation of treatment through therapeutic drug monitoring and Bayesian 
forecasting.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 2-018-0727-5) contains 
supplementary material, which is available to authorized users.
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Key Points 
Current dosing recommendations fail to achieve consist-
ent vancomycin exposure throughout life and across 
patient subgroups.
This pharmacokinetic model for vancomycin adequately 
characterises vancomycin pharmacokinetics across a 
broad range of patient populations, including those at the 
extremes of age and weight.
1 Introduction
The glycopeptide antibiotic vancomycin plays an impor-
tant role in the treatment of Gram-positive bacterial infec-
tions. It is currently considered a key therapeutic option 
in the context of the treatment of serious infections (e.g. 
community- and hospital-acquired pneumonia, compli-
cated skin and soft-tissue infections, infective endocardi-
tis) and for the empiric treatment of patients at high risk of 
infections caused by methicillin-resistant Staphylococcus 
aureus or multidrug-resistant Staphylococcus epidermidis 
[1, 2].
Although vancomycin has been in clinical use since 
its first registration almost six decades ago, questions 
with respect to the optimal dosing regimen remain. Con-
sequently, a plethora of reports on subpopulation- and 
context-specific pharmacokinetics and derived dosing 
regimens have surfaced over the last 25 years. In 2012, 
768 P. J. Colin et al.
these numerous population-pharmacokinetic (PK) studies 
led Marsot and co-workers [3] to conclude that initial dos-
ing regimens for vancomycin should depend on creatinine 
clearance and body weight in adults, and creatinine clear-
ance, body weight and age in children. The assessment 
report on vancomycin drug products issued in 2017 by the 
European Medicines Agency [1] is in line with the rec-
ommendations by Marsot and co-workers. Nevertheless, 
it also highlights some known unknowns. For example, 
the report comments that specific dosing regimens might 
be required for neonatal and elderly populations and for 
patients with renal impairment.
Besides getting the initial dose right, optimisation of 
vancomycin exposure entails the use of therapeutic drug 
monitoring (TDM), especially in populations where PK 
variability is large (e.g. preterm neonates, critically ill 
patients) [1]. Individualised dosing based on TDM data is 
most efficiently achieved through Bayesian forecasting of 
PK parameters based on an a priori population-PK model. 
This technology is currently offered by a range of TDM 
software packages [4], such as  DoseMe® (DoseMe Pty 
Ltd., Brisbane, QLD, Australia),  InsightRx® (Insight Rx 
Inc., San Francisco, CA, USA), MwPharm ++® (Mediware 
a.s., Prague, Czech Republic) and DosOpt (University of 
Tartu, Tartu, Estonia) [5].
At present, different vancomycin population-PK models 
are, however, used across these software packages; and 
within a package often different models are used for differ-
ent patient subpopulations. This poses a challenge to clini-
cians who have to consider the limitations of the models 
they utilise. Moreover, the clinician might have to switch 
models when treating different patient populations.
It has previously been shown that when applied to 
external datasets, there are wide differences in the per-
formance of various currently used PK models [6, 7]. In 
anaesthesia, this has led to data-sharing initiatives with 
the intent of replacing different subgroup-specific models 
with a single pooled population-PK model [8, 9]. Such 
a model is expected to be more generalisable than other 
models, making it simpler and more useful for everyday 
clinical use [10].
In this study, we aimed to develop a single PK model 
for vancomycin, derived from a broad dataset covering the 
extremes of patient characteristics. Moreover, as a bench-
mark for current dosing recommendations, we performed 
simulations using the final population-PK model and eval-
uated the expected vancomycin exposure throughout life 
and for specific patient subgroups. Finally, based on these 
simulations optimised doses were recommended.
2  Materials and Methods
2.1  Component Datasets
Studies on vancomycin pharmacokinetics were identi-
fied though a PubMed search (until 27 September, 2017) 
using search terms: “vancomycin AND population AND 
pharmacokinetics [Title/Abstract]” OR “vancomycin AND 
pharmacokinetics [Title/Abstract]”. We excluded studies 
of patients receiving continuous renal replacement ther-
apy, haemodialysis, haemodiafiltration, extra-corporeal 
membrane oxygenation and non-intravenous administra-
tion of vancomycin. Corresponding or senior authors from 
these studies were invited to contribute their anonymised 
data and participate in this modelling study. All studies 
obtained necessary institutional review board approval, 
as declared in the original papers or as declared by the 
corresponding or senior author (personal communication).
Postmenstrual age (PMA), postnatal age (PNA), weight, 
height and serum creatinine (SCR) were extracted from 
the datasets. Postmenstrual age for patients other than 
neonates was assumed to be 40 weeks longer than the 
recorded postnatal age (years). Missing values for SCR 
were imputed as the population median SCR from that 
study. Missing values for height were imputed as the popu-
lation median height from that study or from a similar 
study (for neonatal studies with missing height) or with 
height data from a national health survey in that specific 
population.
Questionable covariate data were corrected whenever 
possible. These primarily concern overlapping drug infu-
sion records and unrealistic combinations of age, weight and 
height within a subject. To avoid computational difficulties 
during model building due to excessively long follow-up 
times, the dataset was restricted to observations from the 
first 31 days of therapy.
2.2  Population‑Pharmacokinetic Modelling
The vancomycin concentration vs. time data were fitted 
using the FOCE-I estimation algorithm in  NONMEM® 
(Version 7.3; GloboMax LLC, Hanover, MD, USA). The 
“tidyverse” package (Version 1.1.1.; Wickham H. 2017) 
in  R® (R Foundation for Statistical Computing, Vienna, 
Austria) was used to graphically assess the goodness of 
fit and for simulations.
As a starting point, one-, two- and three-compartmental 
PK models were fitted to the data. Inter-individual vari-
ability on the typical population parameter estimates was 
assumed to be log-normally distributed. Residual unex-
plained variability was modelled using a combined propor-
tional and additive error model. Inter-occasion variability 
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was not tested in the model owing to difficulties in defining 
an occasion in the context of this dataset where dosing and 
sampling times/frequency vary considerably.
Modifications to the structural and/or covariate model 
were accepted only if they resulted in a decrease in the 
objective function value (OFV) and an increased in-sample 
predictive performance. A decrease in OFV was judged sta-
tistically significant if inclusion of an additional parameter 
decreased the OFV by more than 3.84 points. As a measure 
of in-sample prediction performance, the absolute relative 
prediction errors (APEs) were calculated (Eq. 1) by compar-
ing the measured vancomycin concentrations for each indi-
vidual i at time point j  (VANij) with the population-predicted 
concentrations (PRED). The median of the distribution of 
APEs (MdAPE) was used to compare the imprecision of 
candidate models during model building and to compare the 
final model against earlier published models.
To ascertain that model building was not driven by the 
most populated subgroup, we stratified the calculation of the 
prediction error. The following subgroups were created: pre-
term and term newborns (PMA < 0.87 years), children and 
adolescents (age < 18 years), adults (age < 65 years), elderly 
(age < 80 years), very elderly (age ≥ 80 years), underweight 
adults (age > 18 years and body mass index < 18.5 kg m−2) 
and obese adults (age > 18 years and BMI > 30 kg m−2). Dur-
ing model building, the average MdAPE across the afore-
mentioned subgroups was taken as an overall measure of 
predictive performance. Covariates tested for inclusion in 
the model were: weight (kilograms), PMA (years), PNA 
(days), SCR (mg dL−1), sex, critical illness and presence of 
severe burn injuries. Height and related covariates such as 
body mass index and fat-free mass were not tested as height 
was missing in most neonates and some adults.
2.3  A Priori Included Covariate Models
In line with earlier work by Holford et al. [11] and Ger-
movsek et al. [12, 13] prior to inclusion of additional covari-
ates in the model we corrected for size and maturational 
changes. For this, PK parameters were scaled to weight 
according to allometric theory [14], with an exponent of 
1 for volume terms (V1, V2, V3) and an exponent of 0.75 
for clearance terms (CL, Q2, Q3). A sigmoidal maturation 
function was used to scale clearance with PMA according 
to Eq. 2 with γ defining the steepness of the non-linear rela-
tionship and PMA50 being the PMA when clearance reaches 
50% of maximal values.
(1)
APE(%) =
|||||
VANij − PREDij
PREDij
||||| × 100%.
(2)Maturation function =
PMA훾
PMA훾 + PMA
훾
50
.
2.4  Testing Serum Creatinine as a Covariate 
in the Model
The influence of SCR on clearance was tested using an expo-
nential function as shown in Eq. 3. This function predicts 
decreasing clearance with increasing SCR values with θSCR 
defining the steepness of the relationship. Serum creatinine 
was included in the dataset as a time-varying covariate with 
backward constant interpolation between observations.
Parameter values were standardised by centering SCR 
observations according to a standardised SCR  (SCRstd) 
value. Different approaches for defining  SCRstd were 
compared. A first approach consisted of using the median 
observed SCR from the dataset. Other approaches were 
explored in an effort to derive age-, weight- and sex-adjusted 
 SCRstd values. For this, empiric functions were fitted to the 
covariate data using fractional polynomial regression (R 
package “mfp: Multivariable Fractional Polynomials”; Ver-
sion 1.5.2) in line with the work of Ceriotti et al. [15], or 
custom non-linear models in  R®.
2.5  Evaluation and Optimisation of Current Dosing 
Recommendations
As examples of contemporary dosing guidelines for vanco-
mycin approved by the European Medicines Agency and the 
US Food and Drug Administration (FDA), we used the sum-
mary of product characteristics (SmPC) for “Vancomycin 
500 mg Powder for Solution for Infusion” (Consilient Health 
Ltd; available from www.medic ines.org.uk; consulted on 23 
May, 2018) and the label for “Vancomycin Hydrochloride 
for Injection USP” (ANI Pharmaceuticals, Inc.; available 
from www.fda.gov; consulted on 23 May, 2018). The posol-
ogies outlined by the SmPC and the FDA label are summa-
rised in Tables S1 and S2 of the Electronic Supplementary 
Material (ESM), respectively.
Steady-state vancomycin exposure was simulated using 
the post hoc-predicted clearance for all patients in our data-
set according to Eq. 4:
where AUC 24 h is the area under the concentration–time 
curve for a 24-h period in steady state and DOSE and τ 
are the amount of vancomycin administered and the dosing 
interval, respectively. The predicted AUC 24 h was then used 
to calculate the proportion of patients who were under- and 
over-dosed. Under-dosing was assumed when the AUC 24h 
was below 400 mg L−1 h, a frequently cited threshold for 
(3)FScr = e(−휃SCR×(SCR−SCRstd)).
(4)AUC24 h =
DOSE ×
24
휏
CL
,
770 P. J. Colin et al.
efficacy [16, 17] for the treatment of pathogens with a mini-
mum inhibitory concentration of 1 mg L−1. Over-dosing was 
defined as an AUC 24h exceeding 700 mg L−1 h, a recently 
advocated safety threshold for renal toxicity [18].
In the final part of this study, we attempted to optimise the 
daily doses in the SmPC and the FDA label. For this, in line 
with the above, post hoc-predicted clearance for all patients 
was used to predict the proportion of patients achieving 
an AUC 24h above 400 mg L−1 h and below 700 mg L−1 
h (fTarget). A non-linear optimisation routine based on the 
Nelder-Mead Simplex [19] as implemented in  R® (R pack-
age “nloptr”; Version 1.0.4) was used to optimise fTarget using 
the doses in the SmPC and the label as control variables. For 
practical purposes, optimised daily doses were rounded to 
the nearest 50 mg and 0.5 mg kg−1.
3  Results
3.1  Data
In total, 39 publications were identified. All senior and/or 
corresponding authors for these publications were contacted 
via e-mail on multiple occasions. We obtained 14 previously 
published data sets [20–33]. Our pooled dataset contains 
information across a broad range of patient subgroups rang-
ing from premature neonates [20, 24, 30, 32] to extremely 
obese patients [26] and from adult Japanese healthy volun-
teers [27] to critically ill and trauma patients [25, 31, 33]. 
A summary of the included studies is shown in Table 1. 
The distributions of patient characteristics and vancomycin 
concentrations are shown in Fig. S1 of the ESM. In total, 
8300 vancomycin drug concentrations from 2554 individuals 
were included in the dataset. Individuals were adults (720), 
newborns (559), elderly patients (512), obese adults (274), 
very elderly patients (213), underweight adults, (158) and 
children and adolescents (118).
Initial analysis of the dataset identified outliers (n = 10). 
The data for these individuals were primarily biased because 
of missing dosing information prior to the first observation, 
potential sampling errors (e.g. reported vancomycin con-
centrations > 100 mg L−1) or dosing regimens that were sig-
nificantly different from other comparable individuals from 
the same study. Because of the small number of outliers 
identified (0.4% of individuals), we decided to remove these 
patient records from the dataset.
3.2  Population‑Pharmacokinetic Modelling
We found that a two-compartment model better described 
the data compared with a one-compartment model 
(ΔOFV = − 1155). A three-compartment model had a lower 
OFV (ΔOFV = − 85). However, goodness-of-fit plots for 
both models were indistinguishable and likelihood profil-
ing [34] revealed high uncertainty on the estimate for the 
inter-compartmental clearance to the slow peripheral com-
partment (Q3). Therefore, we decided to retain the two-
compartment model as the final model.
We found significant maturation in vancomycin clearance, 
with 50% of maximal clearance being reached by 46.4 weeks 
PMA  (PMA50). After correcting for maturation, it became 
apparent that vancomycin clearance deteriorates with age-
ing. The sigmoidal function fitted to describe the declining 
clearance with age revealed that 50% of maximal clearance 
is lost by 61.6 years PMA  (AGE50). Figure 1 shows the 
typical-for-PMA standardised clearance (L h−1 70 kg−1) for 
all patients in our dataset. Figure 1 also shows the matura-
tion–decline function as estimated by Lonsdale et al. [35] in 
a recent pooled analysis of three commonly used beta-lactam 
antibiotics.
After accounting for size- and age-related changes in van-
comycin pharmacokinetics, we tested the influence of SCR 
on clearance according to Eq. 3. Table 2 provides an over-
view of the different model building steps and shows the dif-
ferent approaches taken to define  SCRstd. When the median 
observed SCR (0.80 mg dL−1 or 70.7 µmol L−1) is used 
as  SCRstd, the lowest OFV is obtained (ΔOFV = − 1810). 
However, this approach led to an increase in the estimates for 
 PMA50 and  AGE50. A fractional polynomial model relating 
 SCRstd to PNA, gestational age, weight and sex performed 
less well (ΔOFV = − 1692). However, standardisation of 
SCR values using this approach had no influence on the 
estimates for  PMA50 and  AGE50. Ultimately, we found that 
the empiric function producing the lowest OFV with the 
least influence on the estimates for  PMA50 and  AGE50 was 
a non-linear function relating  SCRstd to PMA (Eq. 5).
A plot of the predicted  SCRstd as a function of PMA is 
shown in Fig. S2 of the ESM. Figure S2 also shows the 
 SCRstd used in the work of Johansson et al. [36] and Hen-
nig et al. [37], which is based on the reference intervals 
reported by Ceriotti et al. [15] and Junge et al. [38] When 
we implemented the latter approach, we found a similar 
decrease in OFV compared to our best performing function 
(ΔOFV = − 1790 vs. −1805, respectively). However, as seen 
in Table 2, under this approach the estimates for  PMA50 
and  AGE50 slightly increase (+1.8 weeks and +4.1 years, 
respectively). Furthermore, as seen in Fig. S2 of the ESM, 
the predicted  SCRstd does not align well with the median of 
our observed SCR values. Therefore, we decided to include 
the empiric function described in Eq. 5 in our final model. 
The inclusion of SCR decreased in-sample MdAPEs for all 
subgroups ranging from − 0.7% for children and adolescents 
(5)SCRstd = e(−1.228+log10 (PMA(yr))×0.672+6.27×e
(−3.11×PMA(yr)).
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to − 10.2% in elderly patients. Inclusion of SCR as a base-
line covariate rather than a time-varying covariate was sig-
nificantly worse (ΔOFV = + 876).
At this step in model development, we tested compart-
mental allometry for clearance and Q2, scaling them allomet-
rically to the estimated size of the corresponding compart-
ment (V1 and V2). In line with earlier work on propofol [8], 
remifentanil [9] and dexmedetomidine [39], compartmen-
tal allometry improved the goodness of fit (ΔOFV = − 212) 
without disturbing the interpretation of the fixed-effect 
parameters in the models.
Altered pharmacokinetics was observed in two composite 
datasets. On the one hand, in the study by Buelga and co-
workers on patients with haematological malignancies [29], 
clearance was significantly higher (+29.4%). On the other 
hand, the study by Lo and co-workers [32], who used heel-
prick sampling as opposed to arterial/venous sampling, we 
found a lower V1 (− 31.2%) and Q2 (− 59.7%). Accounting 
for these subgroup-specific effects resulted in a better fit 
(ΔOFV = − 184 and − 115, respectively).
To achieve adequate numeric stability of the model, i.e. 
smooth gradient minimisation and acceptable likelihood 
profiles, we removed the estimate for the population vari-
ability on Q2 (ΔOFV = + 5.0).
The final population-PK model is shown in Eqs. 6–13 and 
Table 3, the NONMEM output for the final model is shown 
in the ESM.
(6)
CL(L h−1) = 휃
CL
×
(
V1
휃V1
)0.75
× F
Mat
× F
Decline
× F
SCR
×
(
1 + 휃
STDY10
)
× e휂1
(7)V1(L) = 휃V1 ×
(
FSize
)1
×
(
1 − 휃STDY13_V1
)
× e휂2
(8)V2(L) = 휃V2 ×
(
FSize
)1
× e휂3
(9)Q2(L h−1) = 휃Q2 ×
(
V2
휃V2
)0.75
×
(
1 − 휃STDY13_Q2
)
(10)FSize =
WGT(kg)
70
Fig. 1  Standardised clearance 
 [CLstd] (L h−1 70 kg−1) for 
vancomycin throughout life. 
Typical vancomycin clearance 
according to our final model 
is shown with a solid black 
line. Post-hoc  CLstd values for 
all patients in our dataset are 
shown with solid grey circles. 
The grey shaded area denotes 
the region between the 10 and 
90% percentile of all observa-
tions. The dashed black line is 
the maturation–decline function 
for beta-lactam antibiotics 
according to Lonsdale et al. [35] 
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In these equations, CL (L h−1) is vancomycin clearance, 
V1 (L) and V2 (L) are the central and peripheral volume 
of distribution and Q2 (L h−1) is the inter-compartmental 
clearance. FSize, FMat, FDecline and FSCR describe size-related 
changes, maturational changes, age-induced deterioration 
and SCR-related changes in vancomycin pharmacokinetics, 
respectively. θSTDY10, θSTDY13_V1 and θSTDY13_Q2 denote the 
increased clearance in patients with haematological malig-
nancies and the effect of heel-prick sampling on V1 and Q2. 
Symbols η1–η3 denote inter-individual variability (with vari-
ances ω1–ω3) of the typical PK parameters.
Backwards elimination of FSize, FMat, FDecline or FSCR from 
the model consistently resulted in an increased OFV and 
increased unknown inter-individual variability in clearance 
(data not shown). Goodness-of-fit plots for the final model 
are shown in Fig. 2. Figures S3, S4 and S5 of the ESM 
show the goodness-of-fit plots stratified by study and the 
prediction-variance-corrected visual predictive check [40] 
for the pooled data and data stratified by patient category, 
(11)FMat =
PMA(wk)훾1
PMA(wk)훾1 + PMA
훾1
50
(12)FDecline =
PMA(yr)−훾2
PMA (yr)−훾2 + AGE
훾2
50
(13)FSCR = e(−휃SCR×(SCR(mgdL
−1)−SCRstd)),
respectively. Overall, these diagnostics show that our final 
model is adequately developed.
3.3  Evaluation and Optimisation of Current Dosing 
Recommendations
The distribution of predicted steady-state vancomycin 
AUC 24h resulting from the dosing recommendations in the 
SmPC and the FDA label are shown in Fig. 3. The propor-
tion of patients achieving an AUC 24h below 400 mg L−1 h 
(fAUC<400), between 400 and 700 mg L−1 h (fTarget), and above 
700 mg L−1 h (fAUC>700) are shown in Tables S3 and S4 of 
the ESM.
Based on the dosing regimen in the SmPC, 19% of 
patients attain an AUC 24h below 400 mg L−1 h, whilst 46% 
of patients attain an AUC 24h above 700 mg L−1 h. Elderly 
(76%), very elderly (70%) and obese patients (81%) are 
mainly at risk for attaining a steady-state AUC 24h above 
700 mg L−1 h, whereas for underweight adults (25%), new-
borns (43%), and children and adolescents (65%) a consider-
able proportion of patients is expected to attain an AUC 24h 
below 400 mg L−1 h.
The dosing regimens in the FDA-approved label result in 
a more consistent steady-state exposure with a very low risk 
of attaining an AUC 24h above 700 mg L−1 h across patient 
subgroups. However, except for newborns, all patient sub-
groups are significantly at risk for a steady-state AUC 24h 
below 400 mg L−1 h, with probabilities ranging from 52% 
in very elderly patients to 70% in children and adolescents.
The optimised daily doses for the SmPC and FDA label 
are shown in Table 4. In general, optimised daily doses are 
Table 3  Parameter estimates 
and associated relative standard 
errors (RSEs) for the final 
population-pharmacokinetic 
model. Inter-individual 
variability (IIV) associated 
with the typical parameters 
is expressed as coefficient of 
variation %
a Calculated according to: 
√
e휔 − 1 × 100%
b Derived from log-likelihood profiling
c Expressed as standard deviation
Final model
Parameter Estimate (RSE %b) IIVa (RSE %b) η Shrinkage,  %
휃CL (L h−1 70 kg−1) 5.31 (1.6) 27.9 (3.2) 29.8
휃V1 (L 70 kg−1) 42.9 (1.9) 27.3 (9.8) 42.7
휃V2 (L 70 kg−1) 41.7 (3.5) 97.9 (5.7) 47.0
휃Q2 (L h−1 70 kg−1) 3.22 (7.1) – –
PMA50 (wk) 46.4 (4.2) – –
γ1 2.89 (7.6) – –
AGE50 (y) 61.6 (4.0) – –
γ2 2.24 (6.5) – –
휃SCR 0.649 (2.3) – –
휃STDY10 0.294 (9.2) – –
휃STDY13_V1 0.312 (11) – –
휃STDY13_Q2 0.597 (10) – –
Residual error (proportional) 21.5 (3.2) – –
Residual error (additive)c 1.23 (9.8) – –
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higher. Exceptions are adults and children with an estimated 
glomerular filtration rate < 50 mL.min−1, where the opti-
mised daily doses for the SmPC are 14.5 and 28.5 mg kg−1 
instead of 15 and 30 mg kg−1. For both the optimised SmPC 
and the FDA label, fTarget increases consistently across sub-
groups with the overall fTarget increasing from 35 to 46% and 
37 to 60% for the SmPC and the FDA label, respectively. For 
the optimised label, fTarget is > 50% in all subgroups and the 
risk for over- or under-dosing is consistent (± 20%) across 
subgroups. However, for the optimised SmPC, children and 
adolescents (30%) and underweight adults (46%) remain at 
risk for under-dosing, whereas elderly patients (46%), very 
elderly patients (53%) and obese patients (58%) are at risk 
for over-dosing.
4  Discussion
In this population-PK modelling study, we showed that van-
comycin pharmacokinetics undergoes significant changes 
throughout human life. Besides size-related changes in 
clearance, maturation is the main driver for clearance 
during early childhood with 90% of adult clearance being 
reached by 2 years PMA. Between 3 and 16 years PMA, 
size-corrected clearance is highest (> 5.05 L h−1 70 kg−1). 
Afterwards, clearance deteriorates significantly, reach-
ing 2.66 h−1 70 kg−1 (i.e. 50% of maximum clearance) by 
61.6 years PMA. Not surprisingly, we found that SCR is 
a significant covariate on clearance for both between- and 
within-subject variability. When SCR decreases or increases 
0.20 mg dL−1 (17.7 µmol L−1) from the typical-for-PMA 
 SCRstd, clearance changes with + 13.8 and − 12.2%, 
respectively.
According to our model, typical vancomycin clearance 
in a 60-year-old, 65-kg patient with a SCR of 0.97 mg dL−1 
(85.7 µmol.L−1) is 2.55 L h−1 (0.039 L h−1 kg−1). Vancomy-
cin clearance in a 32-week, 1.5-kg neonate with a SCR of 
0.64 mg dL−1 (56.6 µmol L−1) is 0.0756 L h−1 (0.0504 L.h−1.
kg−1). Both values are in line with the range of clearance 
estimates reported by Marsot et al. 3 for adults (0.031–0.086 
L h−1 kg−1) and paediatric patients (0.020–0.112 L h−1 kg−1). 
In contrast to Marsot et al. [3] who reported different esti-
mates for vancomycin volume of distribution for adults 
(0.864 L kg−1) and children (0.565 L kg−1), we found that 
Fig. 2  Goodness-of-fit plots for 
the final population-pharma-
cokinetic model. Scatterplots 
show the distribution of the 
observed vancomycin con-
centrations (Observed Cplasma) 
vs. population and individual 
predictions and the (absolute) 
conditionally weighted residuals 
(|CWRES| and CWRES) vs. 
individual predictions and time 
after the end of the dose. Nega-
tive times denote observations 
taken when drug was infused, 
whereas positive times are 
observations after stopping the 
infusion. A dashed line denotes 
the line of unity or the zero line, 
whilst a red solid line shows a 
non-parametric smoother
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the size-standardised volume of the distribution is constant 
throughout life at 0.61 L.kg−1 for V1 and 0.59 L kg−1 for V2.
Our estimate for  PMA50 of 46.4 weeks is in good agree-
ment with earlier work by Rhodin et al. [41] who found that 
glomerular filtration function reaches 50% of adult values 
by 47.7 weeks PMA. This suggests, in line with previous 
reports [42], that vancomycin elimination depends pre-
dominantly on glomerular filtration. Moreover, our  PMA50 
estimate is not significantly different from the findings of 
Anderson et al. [20] who reported a  PMA50 of 33.3 weeks 
(95% confidence interval 14.8–51.8) in a cohort of preterm 
neonates. It also inspires confidence that our conclusion of 
maturation being nearly complete at 2 years PMA is sup-
ported by a recent physiologically based PK simulation 
study by Calvier et al. [43].
Model building started out with an a priori model con-
sisting of allometric scaling and a maturation function as 
advocated by Holford et al. [11] and more recently by Ger-
movsek et al. [12]. By extending this standardised model 
with an additional sigmoidal decline function, we were 
able to describe the deterioration in vancomycin clearance 
with age. Recently, Lonsdale et al. [35] have used the same 
methodology to describe beta-lactam antimicrobial pharma-
cokinetics from early life to old age. Notwithstanding that 
tubular secretion and/or re-absorption are likely involved in 
beta-lactam elimination, these authors found a  PMA50 esti-
mate of 49.7 weeks, which is in line with our findings. Their 
estimated  AGE50 of 86.8 years, however, is significantly 
higher than what we found for vancomycin (61.6 years). In 
addition to differences in elimination processes, the differ-
ent handling of renal function in the study by Lonsdale et al. 
[35] compared with our analysis might explain the differ-
ent  AGE50 estimates. Indeed, as seen from Table 2, dur-
ing model building,  AGE50 ranged from 67.4 to 79.8 years 
depending on the method used to standardise SCR.
This is by far the largest population-PK modelling study 
on vancomycin pharmacokinetics. On the one hand, our 
findings confirm earlier fragmented findings on the influence 
of weight, kidney function and age on vancomycin pharma-
cokinetics by other groups [3] as well as the increased clear-
ance in patients with haematological diseases [29]. On the 
other hand, we were able to negate some prior hypotheses. 
Fig. 3  Simulated area under 
the concentration–time curve 
at steady state for a 24-h period 
(AUC 24h) according to the 
different patient groups in the 
summary of product character-
istics (SmPC) and the US Food 
and Drug Administration (FDA) 
label. White boxplots show the 
AUC 24h distributions resulting 
from the original SmPC and 
FDA label whereas grey box-
plots show the distribution of 
AUC 24h for the optimised doses 
for the SmPC and the label. The 
grey shaded area denotes the 
target exposure, i.e. an AUC 
24h between 400 mg L−1 h and 
700 mg L−1 h. EMA European 
Medicines Agency
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We found that after correcting for age, body size and kidney 
function, PK parameters were not different between patients 
with or without burns [23], between critically ill or non-
critically ill patients [25], or between patients treated with 
intermittent or continuous dosing [44]. In addition, we found 
no differences in PK parameters with respect to the different 
vancomycin assay methods used (i.e. assays based on fluo-
rescence polarisation or turbidimetric inhibition principles) 
[45]. Supportive evidence for these findings is provided in 
Figs. S6–S9 of the ESM.
Patients from two studies differed significantly from the 
rest of the population, thereby forcing us to include two 
study-specific parameters. First, patients in the Buelga et al. 
study [29] had a significantly higher clearance. This finding 
is in line with earlier work by Jarkowski et al. [46] and Zhao 
et al. [47] who found higher clearance in adult and paediatric 
patients with malignant haematological diseases. Second, 
the concentration–time profile for patients in the Lo et al. 
study [32] was different from other studies. This is likely 
owing to the heel prick sampling that was used in the Lo 
et al. study as opposed to venous or arterial blood sampling 
in the other studies. This reasoning is in line with earlier 
work by Chiou who showed that drug concentrations depend 
on the sampling site [48].
Using the post hoc PK parameters derived from our 
model, we evaluated two currently used dosing regimens 
for vancomycin and showed that these dosing regimens do 
not consistently result in efficacious and safe steady-state 
vancomycin exposure across patient populations. The opti-
mised daily doses increase the proportion of patients attain-
ing an AUC 24h between 400 and 700 mg L−1 h for both the 
European Medicines Agency-approved SmPC and the FDA-
approved label. From these simulations, we see that weight-
based dosing for neonates is acceptable, yet the dose-per-kil-
ogram should be increased. For adults, weight-based dosing 
is inappropriate and results in under-dosing of underweight 
adult patients whilst obese adult patients are generally over-
dosed. Moreover, age- or kidney function-adjusted dosing is 
necessary to avoid over-dosing in elderly patients and very 
elderly patients. The optimised FDA label, which defines 
kidney function-adjusted doses for patients aged older than 
18 years and weight-based dosing otherwise, performs well 
Table 4  Posology from the US Food and Drug Administration (FDA) 
label for “Vancomycin Hydrochloride for Injection USP” from the 
FDA website (www.fda.gov; consulted on 23 May, 2018) and the 
summary of product characteristics for “Vancomycin 500 mg Powder 
for Solution for Infusion” available from www.medic ines.org.uk (con-
sulted on 23 May, 2018)
ND not determined, as our study only included two adult patients with eGFR < 10 mL min−1, PMA postmenstrual age, PNA postnatal age
a eGFRadult estimated glomerular filtration rate according to: eGFRadults
(
mLmin−1
)
=
Weight(kg)×(140−age(yr))
72×serum creatinine(mgdL−1)
× 0.85 (if female) or 
eGFRadults
(
mLmin−1
)
=
Weight(kg)×(140−age(yr))
serum creatinine(μmolL−1)
× 1.04(if female) × 1.23(if male)
b eGFRpeds: estimated glomerular fitration rate according to: eGFRpeds
(
mLmin−11.73 m−2
)
=
Height(cm)×0.413
serum creatinine(mgdL−1)
 or 
eGFRpeds
(
mLmin−11.73 m−2
)
=
Height(cm)×36.2
serum creatinine(μmolL−1)
FDA label for “Vancomycin Hydrochloride for Injection USP” Summary of product characteristics for “Vancomycin 500 mg 
Powder for Solution for Infusion”
Patient subgroup Renal function 
adjustments
Daily dose Optimised daily 
dose
Patient subgroup Renal function 
adjustments
Daily dose 
(mg kg−1)
Optimised 
daily dose 
(mg  kg−1)
Neonates < 1 wk 
PNA
– 20 mg kg−1 25.0 mg kg−1 Neonates < 29 wk 
PMA
15 23.5
Neonates < 1 mo 
PNA
– 30 mg kg−1 34.0 mg kg−1 Neonates < 35 wk 
PMA
30 35.0
1 mo PNA > chil-
dren > 18 yr
– 40 mg kg−1 61.0 mg kg−1 Neonates < 1 mo 
PNA
45 54.0
Adults – 2000 mg 3000 mg 1 mo PNA > chil-
dren > 12 y
eGFRpedsb ≤ 29 15 19.0
Adults with 
impaired renal 
function
eGFRadulta < 100 1545 mg 1800 mg eGFRpeds ≤ 50 30 28.5
eGFRadult < 90 1390 mg 1800 mg eGFRpeds > 50 40 73.0
eGFRadult < 80 1235 mg 1650 mg Adults eGFRadult < 50 15 14.5
eGFRadult < 70 1080 mg 1550 mg eGFRadult ≥ 50 40 43.0
eGFRadult < 60 925 mg 1450 mg
eGFRadult < 50 770 mg 1200 mg
eGFRadult < 40 620 mg 900 mg
eGFRadult < 30 465 mg 650 mg
eGFRadult < 20 310 mg 350 mg
eGFRadult < 10 155 mg ND
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with consistent target attainment and minimal (± 20%) risk 
of under- and over-dosing across patient subgroups.
These recommendations should be interpreted by taking 
into account that: (1) further optimisation of these dosing 
regimens could be achieved by further stratifying patient 
subgroups based on age and/or weight; (2) the thresholds 
used for defining adequate and or excessive AUC 24h are still 
under debate and regional differences exist in minimum 
inhibitory concentration distributions; and (3) TDM is still 
necessary to further optimise the treatment of individual 
patients. Furthermore, our study excluded specific patient 
categories (patients receiving renal replacement therapy, 
haemodialysis, haemodiafiltration and extra-corporeal mem-
brane oxygenation) and in the pooled dataset some patient 
categories were only sparsely populated (e.g. the group of 
children and adolescents). As such, the generalisability 
of our results and the predictive performance of the final 
model should be validated in a prospective study prior to 
implementation of the model or derived recommendations 
in clinical practice.
5  Conclusion
In this article, we show that vancomycin pharmacokinet-
ics changes dramatically throughout human life and a sin-
gle population-PK model is able to capture these changes. 
Through simulations, we showed that current dosing regi-
mens do not succeed in providing similar steady-state expo-
sure across patient subgroups and as such the probability 
for therapeutic success or vancomycin-induced toxicity is 
not constant throughout life. As illustrated in this work, this 
new model has the potential to overcome these limitations 
and could be used to further develop age- and renal func-
tion-specific dosing regimens for vancomycin. Furthermore, 
this model could facilitate individualised vancomycin dos-
ing through Bayesian forecasting based on therapeutic drug 
monitoring.
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